Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2009
2010
2013
2017
2019
2021
2022
2024
2025
Aspire Pharma incorporated in the UK
1st brand launch: iAluRil
The first products within the Pathway Portfolio of generic medicines launched in the UK. This portfolio covers a wide and expanding range of therapy areas, including urology, CNS, respiratory and more.
Aspire further diversifies into an ophthalmology range
Acquisition of DermatoLogical Ltd, forming Aspire’s dermatology franchise and branded later as EPIMAX
H.I.G. Capital acquires a majority stake in Aspire
The Morningside companies acquired - creating a united business with a combined portfolio of 250+ niche generics
Global licensing agreement for Retinol owned by Orphanix GmbH
Acquisition of assets from Canute Pharma Ltd
Cenote Pharma Ltd acquired
Aspire Ireland (APIE) legal entity and office established
Tetris Pharma UK distribution product rights acquired
Aspire Germany field office opened
↑
↓
